Related Experiment Video

Updated: May 26, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML

W-H Lin1, W-T Jiaang, C-W Chen

  • 1Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan, Miaoli County 350, Taiwan.

British Journal of Cancer
|December 22, 2011
PubMed
Abstract

Insights

A new FLT3 inhibitor, BPR1J-097, effectively targets acute myeloid leukemia (AML) by inhibiting FLT3 kinase activity and inducing apoptosis. This potent compound demonstrated significant anti-tumor effects in preclinical models, suggesting its therapeutic potential for AML treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Activating mutations in Fms-like tyrosine kinase 3 (FLT3) are key drivers in acute myeloid leukemia (AML) pathogenesis.
  • Targeting FLT3 with pharmacological inhibitors is a promising therapeutic strategy for AML.

Purpose of the Study:

  • To investigate the anti-leukemic effects of a novel potent FLT3 inhibitor, BPR1J-097.
  • To evaluate the in vitro and in vivo efficacy of BPR1J-097 in FLT3-driven AML models.

Main Methods:

  • In vitro kinase inhibition assays to determine IC50 values.
  • Cell growth inhibition assays (GC50) on AML cell lines (MOLM-13, MV4-11).
  • In vivo studies using murine xenograft models of FLT3-driven AML.

Main Results:

  • BPR1J-097 exhibited potent FLT3 kinase inhibition with IC50 values of 1-10 nM.
  • The compound demonstrated significant growth inhibition in AML cell lines (GC50: 21±7 nM for MOLM-13, 46±14 nM for MV4-11).
  • BPR1J-097 inhibited FLT3 signaling, induced apoptosis, and showed dose-dependent tumor growth inhibition and regression in vivo.

Conclusions:

  • BPR1J-097 is a novel small molecule inhibitor of FLT3 with potent in vitro and in vivo anti-AML activity.
  • The compound possesses favorable pharmacokinetic properties and significant anti-tumor efficacy.
  • BPR1J-097 warrants further preclinical and clinical development as a potential therapeutic agent for AML.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...